Gregory Steinmetz, MD
Family Medicine · Warwick, RINPI 1043294630
Payments from drug & device makers
Across 467 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Pfizer$1K
- Novo Nordisk$845
- AbbVie$489
- AstraZeneca$415
- Lilly USA, LLC$358
- plus $3K from 30 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$150
What the payments were for
- Food & beverage$7,568100%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 110 | $1,819 |
| Pfizer | 114 | $1,073 |
| Novo Nordisk | 44 | $845 |
| AbbVie | 24 | $489 |
| AstraZeneca | 23 | $415 |
| Lilly USA, LLC | 17 | $358 |
| Johnson & Johnson | 19 | $348 |
| Abbott | 18 | $321 |
| Bayer | 13 | $231 |
| Sanofi-aventis U.S. LLC | 12 | $222 |
| Boehringer Ingelheim | 9 | $196 |
| Amgen | 8 | $179 |
| E.r. Squibb & Sons, L.L.C. | 9 | $153 |
| Novartis | 8 | $143 |
| Aimmune Therapeutics, Inc. | 3 | $80 |
| Exact Sciences | 3 | $75 |
| Nestle Healthcare Nutrition Inc. | 3 | $65 |
| Merck | 4 | $62 |
| Xeris Pharmaceuticals, Inc. | 3 | $54 |
| Biohaven Pharmaceuticals, Inc. | 2 | $53 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $43 |
| Astellas Pharma US Inc | 2 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| Mylan Specialty L.p. | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $22 |
| Dexcom, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Verona Pharma, Inc. | 1 | $19 |
| Circassia Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Lucid Diagnostics Inc. | 1 | $13 |
How this compares
$7,597 in reported general payments places this provider in the 90th percentile of 222 family medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 103 | $102,639 |
| EliquisApixaban | 91 | $72,657 |
| JardianceEmpagliflozin | 68 | $56,207 |
| XareltoRivaroxaban | 35 | $34,019 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $31,285 |
| TrulicityDulaglutide | 28 | $27,200 |
| FarxigaDapagliflozin Propanediol | 15 | $24,943 |
| RybelsusSemaglutide | 12 | $19,462 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $19,273 |
| Repatha SureclickEvolocumab | 12 | $16,001 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $15,826 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $15,229 |
| Atorvastatin Calcium | 415 | $5,725 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $5,169 |
| Arnuity ElliptaFluticasone Furoate | 12 | $3,163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $845 | $122,101115 claims |
| PfizerEliquis | $1,073 | $72,65791 claims |
| Boehringer IngelheimJardiance | $196 | $56,20768 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,819 | $50,27467 claims |
| Johnson & JohnsonXarelto | $348 | $34,01935 claims |
| Lilly USA, LLCTrulicity | $358 | $27,20028 claims |
| AstraZenecaFarxiga | $415 | $24,94315 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $222 | $19,27323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 222 family medicine providers in Rhode Island.
Other family medicine in Warwick
- Mark TurshenWarwick$249K
- Patrick MalloyWarwick$19K
- John HoranWarwick$9K
- Michael RekasWarwick$8K
- Martin KerzerWarwick$7K
- Chad LamendolaWarwick$4K
- Keith CallahanWarwick$4K
- Tej BansalWarwick$4K
- Kethelyne BeauvaisWarwick$3K
- Joseph GrandeWarwick$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.